Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 67 |
| Active Pipeline (Recruiting Now) | 37 (22) |
| Completed vs Stopped Early | 11 / 18 (26.9%) |
| Median Closed Actual Enrollment | 15 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Maryland Medical Center | Baltimore, MD | 10 |
| University of Maryland | Baltimore, MD | 6 |
| University of Maryland/Greenebaum Cancer Center | Baltimore, MD | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05615844 | Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the University of Maryland, Baltimore Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.